Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pulse Biosciences CS (NQ: PLSE )

4.160 +0.080 (+1.96%)
Streaming Delayed Price Updated: 2:36 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pulse Biosciences CS

< Previous 1 2 3 4 Next >
Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Clarifies Details of Recent S-3 Filing
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces $65 Million Private Placement
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium
From Pulse Biosciences
Via Business Wire
Pulse Biosciences Reports Third Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Second Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. (NASDAQ:PLSE) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 06/03/2022 -- Certain directors of Pulse Biosciences, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Pulse Biosciences, Inc. Announces Changes to its Rights Offering
From Pulse Biosciences
Via Business Wire
Pulse Biosciences Reports First Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.